CuraFi
  • Home
  • Platform
  • Health Plans
  • Blog
  • Drug Index
  • About Us
  • Contact
Sign in Subscribe

Payor

Hyaluronic Acid Injections: The Economic Impact of an Unnecessary Healthcare Expenditure

Hyaluronic Acid Injections: The Economic Impact of an Unnecessary Healthcare Expenditure

Despite over 50 years of evidence and numerous studies, hyaluronic acid injections for knee osteoarthritis show minimal benefit over placebos, draining significant resources from the American healthcare system. The expenditures surpass a staggering $400 million annually in Medicare claims in 2019 with an estimated one in seven patients with osteoarthritic
Vish Banthia Sep 29, 2023
Navigating the Impact of Semaglutide (GLP-1) on Health Plans and Risk-Bearing Entities

Navigating the Impact of Semaglutide (GLP-1) on Health Plans and Risk-Bearing Entities

By Andrew Ninh In the realm of U.S. healthcare, the arrival of Semaglutide and other GLP-1s has triggered a cascade of responses among varied stakeholders. These drugs present a game-changer in treating diabetes and obesity, requiring a detailed exploration of their implications on diverse health plans and risk-bearing entities,
Andrew Ninh Sep 29, 2023
State of Biosimilars in 2023 and Looking Ahead to 2024

State of Biosimilars in 2023 and Looking Ahead to 2024

As 2023 draws to a close, the world of pharmaceuticals is abuzz with the transformative potential of biosimilars. Unlike traditional generic drugs, which are exact replicas of small-molecule branded medications, biosimilars are near-copies of complex biologic drugs produced by different manufacturers. The burgeoning biosimilar market in the U.S. is
Andrew Ninh Sep 26, 2023

Subscribe to CuraFi

Don't miss out on the latest news. Sign up now to get access to the library of members-only articles.
Cura Financial, Inc. © 2025.